Japanese investors continue to show strong interest in vaccine bonds

Restricted Access Library

The material in this Restricted Access Library is intended to be accessed only by persons with residence within the territory of a Member State of the European Union and is not intended to be viewed by any other persons. The material in this Restricted Access Library is provided by IFFIm for information purposes only and the materials contained herein were accurate only as of their respective dates. Certain information in the materials contained herein is not intended to be, and is not, current. IFFIm accepts no obligation to update any material contained herein.

Persons with residence outside the territory of a Member State of the European Union who have access to or consult any materials posted in this Restricted Access Library should refrain from any action in respect of the securities referred to in such materials and are otherwise required to comply with all applicable laws and regulations in their country of residence.

The materials in this Restricted Access Library are for distribution only to persons who are not a "retail client" within the meaning of section 761G of the Corporations Act 2001 of Australia and are also sophisticated investors, professional investors or other investors in respect of whom disclosure is not required under Part 6D.2 of the Corporations Act 2001 of Australia and, in all cases, in such circumstances as may be permitted by applicable law in any jurisdiction in which an investor may be located.

The materials in this Restricted Access Library and any documents linked from it are not for access or distribution in any jurisdiction where such access or distribution would be illegal. All of the securities referred to in this Restricted Access Library and in the linked documents have been sold and delivered. The information contained herein and therein does not constitute an offer for sale in the United States or in any other country. The securities described herein and therein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws.

Each person accessing the Restricted Access Library confirms that they are a person who is entitled to do so under all applicable laws, regulations and directives in all applicable jurisdictions. Neither IFFIm nor any of their directors, employees, agents or advisers accepts any liability whatsoever for any loss (including, without limitation, any liability arising from any fault or negligence on the part of IFFIm or its respective directors, employees, agents or advisers) arising from access to Restricted Access Library by any person not entitled to do so.

Uridashi offerings by the International Finance Facility for Immunisation have proved remarkably popular with Japanese retail investors

THIS DOCUMENT IS NOT AN OFFER FOR THE SALE OF SECURITIES. THIS DOCUMENT AND THE INFORMATION CONTAINED HEREIN IS NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, IN OR INTO, DIRECTLY OR INDIRECTLY, THE UNITED STATES

Tokyo, 20 May 2010 - Bonds which raise money to ensure that children in the world's poorest countries can be protected against deadly diseases have proved remarkably popular with Japanese retail investors, particularly women who account for around half the buyers in recent transactions.

Uridashi offerings by the International Finance Facility for Immunisation (IFFIm) since 2008 have raised more than JPY 111 billion equivalent (US$ 1.2 billion).

IFFIm's investors, many of whom are Japanese, can measure their return not only in terms of a market-based interest rate but also in the lives they have helped protect against vaccine-preventable diseases.

Alan Gillespie, Chairman, IFFIm Board

Vaccine bonds

The funds raised by IFFIm, which sells so-called "Vaccine Bonds" on the international capital markets, are used by the GAVI Alliance to support vaccination and health programmes in more than 70 developing countries.

This support has boosted GAVI's grant giving capacity by 100 per cent.

From IFFIm's inception in 2006 to the end of 2008 GAVI has been able to save more than three million lives by accelerating access to immunisation and more than a million additional deaths will be averted as a result of vaccine support given in 2009 and 2010, according to the World Health Organization.

IFFIm will thus have helped GAVI prevent more than four million premature deaths by the end of 2010.

Measure return in lives saved

"IFFIm's investors, many of whom are Japanese, can measure their return not only in terms of a market-based interest rate but also in the lives they have helped protect against vaccine-preventable diseases," said IFFIm Board Chair Alan Gillespie.

"Millions more children who have been immunised will grow up to go to school and later contribute to the future development of their countries as healthy and productive adults."

From November 2006 to April 2010, based on support from eight sovereign donors, IFFIm has raised a total of US$ 2.6 billion on the world's capital markets in seven major offerings to both retail and institutional investors.

"IFFIm is a success. It raises funds in the capital markets at very low cost, giving investors and financial institutions the opportunity to make a difference to millions of children in the poorest countries," said Susan McAdams, Director of Innovative Finance at the World Bank, IFFIm's treasury manager.

Strong partnership

"Japanese investors are keen to help people living in the poorest countries. One way they express their support is by investing in bonds issued by institutions like IFFIm," said Yoshiyuki Arima of the World Bank's Japan office.

"Passing the US$ 1 billion (100 billion yen) milestone would not have been possible without a strong partnership with Japan's banking community."

Daiwa Securities has been the arranger for the largest percentage of these funds. The last uridashi distributed by Daiwa Securities Co. Ltd in March 2010 raised US$ 320 million. Women made up 56 % of the total of over 14,500 investors who participated.

The remainder has been raised thanks to Mitsubishi UFJ Securities International Plc. and HSBC Securities (Japan) Limited working with a group of 20 Japanese securities distributors: Ando Securities Co., Ltd., Daisenhinomaru Shoken, Hirogin Utsumiya Securities Co,. Ltd., The Hongkong and Shanghai Banking Corporation Limited, Tokyo Branch, Ichiyoshi Securities Co., Ltd., Imamura Securities Co., Ltd., Jyoko Shoken Corporation, Kyokuto Securities Co., Ltd., Mito Securities Co., Ltd., Mitsui Securities Co., Ltd., Monex Inc., Okinawa Securities Limited, ORIX Securities Corporation, Rakuten Securities, Inc., SBI Securities Co., Ltd., Shinwa Securities Co., Ltd., Socius Securities Co., Ltd., Takagi Securities Co., Ltd., Toyo Securities Co., Ltd.

JPY111 billion raised for GAVI programmes

Starting with its inaugural uridashi in 2008, IFFIm has issued the following bonds, raising an equivalent of JPY 111 billion (USD 1.2 billion) for GAVI programmes:

ZAR 1.7 billion due March 2010 via Daiwa Securities in March 2008
AUD 45 million due February 2012 via Daiwa Securities issued in February 2009
NZD 179 million due February 2012 via Daiwa Securities issued in February 2009
ZAR 3.17 billion due February 2012 via Daiwa Securities issued in February 2009
USD 105 million due May 2012 via Mitsubishi UFJ issued in May 2009
AUD 50 million due May 2012 via Mitsubishi UFJ issued in May 2009
AUD 70.6 million due June 2013 via HSBC issued in June 2009
ZAR 239 million due June 2013 via HSBC issued in June 2009
ZAR 362.8 million 362.8 million due June 2024 via HSBC issued in June 2009
ZAR 2.5 billion due March 2013 via Daiwa Securities in March 2010

IFFIm, rated AAA/Aaa/AAA, has a financial base consisting of legally-binding grant payments from its sovereign sponsors (currently France, Italy, Norway, South Africa, Spain, Sweden, the Netherlands, and the United Kingdom). The World Bank acts as Treasury Manager for IFFIm. The bond issues provide investors with an opportunity to contribute to IFFIm and the funding of immunisation programmes for children in developing countries while investing in high credit quality notes.

About IFFIm

The International Finance Facility for Immunisation Company (IFFIm) is a multilateral development institution created to accelerate the availability of predictable, long-term funds for health and immunisation programmes through the GAVI Alliance. To date, IFFIm has raised more than US$ 2.6 billion for GAVI programmes. IFFIm's financial base consists of legally binding grant payments from its sovereign sponsors (France, Italy, Norway, South Africa, Spain, Sweden, The Netherlands and the UK), on the basis of which IFFIm issues bonds in the international capital markets. IFFIm is currently rated AAA/Aaa/AAA by Fitch Ratings Limited ("Fitch"), Moody's Investors Service Inc. ("Moody's") and Standard & Poor's Ratings Services ("S&P"). IFFIm was established as a charity with the Charity Commission for England and Wales and is registered in England and Wales as a company limited by guarantee with number 5857343 and as a charity with number 1115413.

About the GAVI Alliance

The GAVI Alliance (formerly the Global Alliance for Vaccines and Immunisation) is a public-private partnership that aims to boost immunisation programmes in more than 70 developing countries. It brings together developing country and donor governments, the World Health Organization, UNICEF, the World Bank, the vaccine industry in both industrialised and developing countries, research and technical agencies, NGOs, the Bill & Melinda Gates Foundation and other private philanthropists. WHO projections from 2000 to 2009 show that through GAVI support 257 million additional children have been vaccinated. This will prevent more than five million premature deaths. GAVI provides vaccines against diphtheria, tetanus, pertussis (DTP) combined with haemophilus influenzae type b (Hib) and hepatitis B in a so-called pentavalent (five antigens in one vaccine). Other vaccines funded by GAVI combat measles, yellow fever, pneumococcal diseases (pneumonia and meningitis) and rotavirus (diarrhoea).

About the World Bank

The World Bank is a global development cooperative owned by 186 member countries. Its purpose is to help its members achieve equitable and sustainable economic growth in their national economies and to find effective solutions to pressing regional and global problems in economic development and environmental sustainability. The goal is to help overcome poverty and improve standards of living for people worldwide. The International Bank for Reconstruction and Development (IBRD), rated Aaa/AAA (Moody's/S&P), is the oldest and largest entity in the World Bank Group and provides funding, risk management tools and credit enhancement to sovereigns. To fund this activity, IBRD has been issuing debt securities in the international capital markets for 60 years. The World Bank is also the Treasury Manager for the International Finance Facility for Immunisation (IFFIm). In that capacity, the World Bank, as IFFIm's agent, manages IFFIm's finances according to prudent policies and standards. This includes IFFIm's funding strategy and its implementation in the capital markets, rating agency and investor outreach, hedging transactions and investment management. The World Bank also coordinates with IFFIm's donors and manages their pledges and payments as well as IFFIm's disbursements for immunisation and health programmes through the GAVI Alliance.

THE SECURITIES REFERRED TO IN THIS DOCUMENT HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR UNDER THE SECURITIES LEGISLATION OF ANY STATE OF THE UNITED STATES, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES, OTHER THAN PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. IFFIm DOES NOT PRESENTLY INTEND TO MAKE A PUBLIC OFFER OF SECURITIES IN THE UNITED STATES OR TO REGISTER ANY SECURITIES UNDER THE SECURITIES ACT. ANY OFFERING OF SECURITIES WILL BE MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM IFFIm AND WILL CONTAIN DETAILED INFORMATION ABOUT IFFIm AND ITS MANAGEMENT AS WELL AS FINANCIAL STATEMENTS. THE SECURITIES REFERRED TO IN THIS DOCUMENT WILL ONLY BE OFFERED OR SOLD OUTSIDE THE UNITED STATES IN OFFSHORE TRANSACTIONS IN RELIANCE ON REGULATION S UNDER THE SECURITIES ACT.

Media contacts
Rachel Winter Jones

Rachel Winter Jones
The World Bank (Paris)
Office: +33 1 4069 3052

Yoshiyuki Arima

Yoshiyuki Arima
World Bank
Tel: +81 3 3597 6650

More on this topic

close icon

modal window here